Which has better valuation and earnings, MLYS or HELP?

Mineralys Therapeutics is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mineralys Therapeutics N/A N/A -$154.65M -$2.05 N/A Cybin N/A N/A -$148M -$4.23 N/A

Is MLYS or HELP more profitable?

Mineralys Therapeutics' return on equity of -27.92% beat Cybin's return on equity. Company Net Margins Return on Equity Return on Assets Mineralys Therapeutics N/A -27.92% -26.98% Cybin N/A -68.27% -58.26%

Does the media prefer MLYS or HELP?

In the previous week, Mineralys Therapeutics and Mineralys Therapeutics both had 4 articles in the media. Mineralys Therapeutics' average media sentiment score of 1.23 beat Cybin's score of 0.50 indicating that Mineralys Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mineralys Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cybin 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor HRMY or HELP?

In the previous week, Harmony Biosciences had 19 more articles in the media than Cybin. MarketBeat recorded 23 mentions for Harmony Biosciences and 4 mentions for Cybin. Harmony Biosciences' average media sentiment score of 1.09 beat Cybin's score of 0.50 indicating that Harmony Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Harmony Biosciences 9 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cybin 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings & valuation, HCM or HELP?

HUTCHMED has higher revenue and earnings than Cybin. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio HUTCHMED $548.51M 3.69 $456.91M N/A N/A Cybin N/A N/A -$148M -$4.23 N/A

Is HCM or HELP more profitable?

HUTCHMED's return on equity of 0.00% beat Cybin's return on equity. Company Net Margins Return on Equity Return on Assets HUTCHMED N/A N/A N/A Cybin N/A -68.27% -58.26%

Does the media favor HCM or HELP?

In the previous week, HUTCHMED and HUTCHMED both had 4 articles in the media. Cybin's average media sentiment score of 0.50 beat HUTCHMED's score of -0.16 indicating that Cybin is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HUTCHMED 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Cybin 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is RAPP or HELP more profitable?

Rapport Therapeutics' return on equity of -24.78% beat Cybin's return on equity. Company Net Margins Return on Equity Return on Assets Rapport Therapeutics N/A -24.78% -23.44% Cybin N/A -68.27% -58.26%

Does the media favor RAPP or HELP?

In the previous week, Rapport Therapeutics had 3 more articles in the media than Cybin. MarketBeat recorded 7 mentions for Rapport Therapeutics and 4 mentions for Cybin. Cybin's average media sentiment score of 0.50 beat Rapport Therapeutics' score of -0.01 indicating that Cybin is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rapport Therapeutics 0 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cybin 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings and valuation, GHRS or HELP?

GH Research is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GH Research N/A N/A -$48.26M -$0.92 N/A Cybin N/A N/A -$148M -$4.23 N/A

Is GHRS or HELP more profitable?

GH Research's return on equity of -19.36% beat Cybin's return on equity. Company Net Margins Return on Equity Return on Assets GH Research N/A -19.36% -18.73% Cybin N/A -68.27% -58.26%

Does the media prefer GHRS or HELP?

In the previous week, GH Research and GH Research both had 4 articles in the media. Cybin's average media sentiment score of 0.50 beat GH Research's score of 0.16 indicating that Cybin is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GH Research 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cybin 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Cybin (HELP) Competitors

$10.99 +0.46 (+4.38%)

As of 01:15 PM Eastern

Compare

HELP vs. MLYS, HRMY, HCM, RAPP, and GHRS

Should you buy Cybin stock or one of its competitors? MarketBeat compares Cybin with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cybin include Mineralys Therapeutics (MLYS), Harmony Biosciences (HRMY), HUTCHMED (HCM), Rapport Therapeutics (RAPP), and GH Research (GHRS). These companies are all part of the "pharmaceuticals" industry.

How does Cybin compare to Mineralys Therapeutics?

Mineralys Therapeutics (NASDAQ:MLYS) and Cybin (NASDAQ:HELP) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, media sentiment, dividends, analyst recommendations, institutional ownership and profitability.

Mineralys Therapeutics currently has a consensus target price of $49.33, suggesting a potential upside of 82.41%. Cybin has a consensus target price of $45.25, suggesting a potential upside of 313.24%. Given Cybin's stronger consensus rating and higher possible upside, analysts plainly believe Cybin is more favorable than Mineralys Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mineralys Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Cybin	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00

84.5% of Mineralys Therapeutics shares are held by institutional investors. Comparatively, 17.9% of Cybin shares are held by institutional investors. 18.9% of Mineralys Therapeutics shares are held by company insiders. Comparatively, 15.0% of Cybin shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Mineralys Therapeutics has a beta of 0.68, indicating that its stock price is 32% less volatile than the broader market. Comparatively, Cybin has a beta of 0.55, indicating that its stock price is 45% less volatile than the broader market.

Mineralys Therapeutics' return on equity of -27.92% beat Cybin's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mineralys Therapeutics	N/A	-27.92%	-26.98%
Cybin	N/A	-68.27%	-58.26%

In the previous week, Mineralys Therapeutics and Mineralys Therapeutics both had 4 articles in the media. Mineralys Therapeutics' average media sentiment score of 1.23 beat Cybin's score of 0.50 indicating that Mineralys Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mineralys Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cybin	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Mineralys Therapeutics is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mineralys Therapeutics	N/A	N/A	-$154.65M	-$2.05	N/A
Cybin	N/A	N/A	-$148M	-$4.23	N/A

Summary

Mineralys Therapeutics beats Cybin on 8 of the 12 factors compared between the two stocks.

How does Cybin compare to Harmony Biosciences?

Harmony Biosciences (NASDAQ:HRMY) and Cybin (NASDAQ:HELP) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation, media sentiment and earnings.

In the previous week, Harmony Biosciences had 19 more articles in the media than Cybin. MarketBeat recorded 23 mentions for Harmony Biosciences and 4 mentions for Cybin. Harmony Biosciences' average media sentiment score of 1.09 beat Cybin's score of 0.50 indicating that Harmony Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Harmony Biosciences	9 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cybin	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

86.2% of Harmony Biosciences shares are held by institutional investors. Comparatively, 17.9% of Cybin shares are held by institutional investors. 11.0% of Harmony Biosciences shares are held by insiders. Comparatively, 15.0% of Cybin shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Harmony Biosciences has higher revenue and earnings than Cybin. Cybin is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harmony Biosciences	$959.90M	2.32	$158.69M	$3.08	12.51
Cybin	N/A	N/A	-$148M	-$4.23	N/A

Harmony Biosciences has a net margin of 18.88% compared to Cybin's net margin of 0.00%. Harmony Biosciences' return on equity of 20.06% beat Cybin's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Harmony Biosciences	18.88%	20.06%	14.15%
Cybin	N/A	-68.27%	-58.26%

Harmony Biosciences has a beta of 0.96, meaning that its share price is 4% less volatile than the broader market. Comparatively, Cybin has a beta of 0.55, meaning that its share price is 45% less volatile than the broader market.

Harmony Biosciences presently has a consensus price target of $45.50, suggesting a potential upside of 18.06%. Cybin has a consensus price target of $45.25, suggesting a potential upside of 313.24%. Given Cybin's stronger consensus rating and higher probable upside, analysts plainly believe Cybin is more favorable than Harmony Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harmony Biosciences	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50
Cybin	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Harmony Biosciences beats Cybin on 12 of the 16 factors compared between the two stocks.

How does Cybin compare to HUTCHMED?

HUTCHMED (NASDAQ:HCM) and Cybin (NASDAQ:HELP) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, media sentiment, earnings, analyst recommendations, valuation and profitability.

HUTCHMED has higher revenue and earnings than Cybin.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HUTCHMED	$548.51M	3.69	$456.91M	N/A	N/A
Cybin	N/A	N/A	-$148M	-$4.23	N/A

8.8% of HUTCHMED shares are held by institutional investors. Comparatively, 17.9% of Cybin shares are held by institutional investors. 3.6% of HUTCHMED shares are held by insiders. Comparatively, 15.0% of Cybin shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

HUTCHMED has a beta of 0.23, meaning that its share price is 77% less volatile than the broader market. Comparatively, Cybin has a beta of 0.55, meaning that its share price is 45% less volatile than the broader market.

HUTCHMED currently has a consensus price target of $14.87, indicating a potential upside of 28.00%. Cybin has a consensus price target of $45.25, indicating a potential upside of 313.24%. Given Cybin's stronger consensus rating and higher probable upside, analysts plainly believe Cybin is more favorable than HUTCHMED.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HUTCHMED	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.17
Cybin	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00

HUTCHMED's return on equity of 0.00% beat Cybin's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HUTCHMED	N/A	N/A	N/A
Cybin	N/A	-68.27%	-58.26%

In the previous week, HUTCHMED and HUTCHMED both had 4 articles in the media. Cybin's average media sentiment score of 0.50 beat HUTCHMED's score of -0.16 indicating that Cybin is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HUTCHMED	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cybin	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Cybin beats HUTCHMED on 7 of the 12 factors compared between the two stocks.

How does Cybin compare to Rapport Therapeutics?

Rapport Therapeutics (NASDAQ:RAPP) and Cybin (NASDAQ:HELP) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, media sentiment, analyst recommendations and valuation.

17.9% of Cybin shares are held by institutional investors. 12.5% of Rapport Therapeutics shares are held by insiders. Comparatively, 15.0% of Cybin shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Rapport Therapeutics has higher revenue and earnings than Cybin. Rapport Therapeutics is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rapport Therapeutics	$20M	105.57	-$111.48M	-$2.60	N/A
Cybin	N/A	N/A	-$148M	-$4.23	N/A

Rapport Therapeutics presently has a consensus target price of $57.86, suggesting a potential upside of 31.06%. Cybin has a consensus target price of $45.25, suggesting a potential upside of 313.24%. Given Cybin's stronger consensus rating and higher possible upside, analysts clearly believe Cybin is more favorable than Rapport Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rapport Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92
Cybin	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00

Rapport Therapeutics' return on equity of -24.78% beat Cybin's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rapport Therapeutics	N/A	-24.78%	-23.44%
Cybin	N/A	-68.27%	-58.26%

Rapport Therapeutics has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market. Comparatively, Cybin has a beta of 0.55, indicating that its stock price is 45% less volatile than the broader market.

In the previous week, Rapport Therapeutics had 3 more articles in the media than Cybin. MarketBeat recorded 7 mentions for Rapport Therapeutics and 4 mentions for Cybin. Cybin's average media sentiment score of 0.50 beat Rapport Therapeutics' score of -0.01 indicating that Cybin is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rapport Therapeutics	0 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cybin	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Rapport Therapeutics beats Cybin on 9 of the 15 factors compared between the two stocks.

How does Cybin compare to GH Research?

GH Research (NASDAQ:GHRS) and Cybin (NASDAQ:HELP) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, analyst recommendations, institutional ownership, risk, profitability and dividends.

GH Research presently has a consensus target price of $40.78, indicating a potential upside of 39.05%. Cybin has a consensus target price of $45.25, indicating a potential upside of 313.24%. Given Cybin's stronger consensus rating and higher possible upside, analysts plainly believe Cybin is more favorable than GH Research.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GH Research	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.67
Cybin	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00

56.9% of GH Research shares are owned by institutional investors. Comparatively, 17.9% of Cybin shares are owned by institutional investors. 41.6% of GH Research shares are owned by insiders. Comparatively, 15.0% of Cybin shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

GH Research has a beta of 1.29, meaning that its share price is 29% more volatile than the broader market. Comparatively, Cybin has a beta of 0.55, meaning that its share price is 45% less volatile than the broader market.

GH Research is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GH Research	N/A	N/A	-$48.26M	-$0.92	N/A
Cybin	N/A	N/A	-$148M	-$4.23	N/A

In the previous week, GH Research and GH Research both had 4 articles in the media. Cybin's average media sentiment score of 0.50 beat GH Research's score of 0.16 indicating that Cybin is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GH Research	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cybin	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

GH Research's return on equity of -19.36% beat Cybin's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GH Research	N/A	-19.36%	-18.73%
Cybin	N/A	-68.27%	-58.26%

Summary

GH Research beats Cybin on 8 of the 12 factors compared between the two stocks.

Get Cybin News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HELP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HELP vs. The Competition

Export

Metric	Cybin	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$765.40M	$11.74B	$6.90B	$12.85B
Dividend Yield	N/A	2.73%	2.60%	9.78%
P/E Ratio	-2.59	791.46	281.41	25.50
Price / Sales	N/A	746.00	572.57	80.05
Price / Cash	N/A	72.42	71.79	50.79
Price / Book	2.44	10.79	12.86	6.08
Net Income	-$148M	$2.82B	$3.49B	$348.34M
7 Day Performance	34.49%	2.76%	2.49%	3.19%
1 Month Performance	85.76%	-1.50%	-2.84%	-2.93%
1 Year Performance	N/A	195.80%	75.71%	21.08%

Cybin Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HELP Cybin	2.7574 of 5 stars	$11.00 +4.4%	$45.25 +311.6%	N/A	$765.68M	N/A	N/A	50
MLYS Mineralys Therapeutics	3.6163 of 5 stars	$26.50 +2.8%	$49.33 +86.2%	+100.2%	$2.13B	N/A	N/A	28	Upcoming Earnings
HRMY Harmony Biosciences	4.5843 of 5 stars	$38.78 +8.9%	$44.38 +14.4%	+9.4%	$2.06B	$868.45M	15.64	200	News Coverage Positive News Earnings Report Analyst Forecast High Trading Volume
HCM HUTCHMED	2.1149 of 5 stars	$11.59 +0.4%	$14.87 +28.3%	-35.8%	$2.02B	$548.51M	N/A	1,796	Earnings Report Gap Up
RAPP Rapport Therapeutics	2.5892 of 5 stars	$42.20 +3.5%	$57.86 +37.1%	+194.1%	$1.95B	N/A	N/A	N/A	News Coverage Earnings Report Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HELP) was last updated on 8/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cybin (HELP) Competitors

HELP vs. MLYS, HRMY, HCM, RAPP, and GHRS

How does Cybin compare to Mineralys Therapeutics?

Summary

How does Cybin compare to Harmony Biosciences?

Summary

How does Cybin compare to HUTCHMED?

Summary

How does Cybin compare to Rapport Therapeutics?

Summary

How does Cybin compare to GH Research?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HELP vs. The Competition

Cybin Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cybin (HELP) Competitors

HELP vs. MLYS, HRMY, HCM, RAPP, and GHRS

How does Cybin compare to Mineralys Therapeutics?

Do analysts rate MLYS or HELP?

Do institutionals & insiders have more ownership in MLYS or HELP?

Which has more volatility and risk, MLYS or HELP?

Is MLYS or HELP more profitable?

Does the media prefer MLYS or HELP?

Which has better valuation and earnings, MLYS or HELP?

Summary

How does Cybin compare to Harmony Biosciences?

Does the media favor HRMY or HELP?

Do insiders and institutionals have more ownership in HRMY or HELP?

Which has better valuation and earnings, HRMY or HELP?

Is HRMY or HELP more profitable?

Which has more volatility & risk, HRMY or HELP?

Do analysts recommend HRMY or HELP?

Summary

How does Cybin compare to HUTCHMED?

Which has preferable earnings & valuation, HCM or HELP?

Do insiders and institutionals believe in HCM or HELP?

Which has more volatility & risk, HCM or HELP?

Do analysts recommend HCM or HELP?

Is HCM or HELP more profitable?

Does the media favor HCM or HELP?

Summary

How does Cybin compare to Rapport Therapeutics?

Do institutionals & insiders have more ownership in RAPP or HELP?

Which has stronger valuation and earnings, RAPP or HELP?

Do analysts recommend RAPP or HELP?

Is RAPP or HELP more profitable?

Which has more risk and volatility, RAPP or HELP?

Does the media favor RAPP or HELP?

Summary

How does Cybin compare to GH Research?

Do analysts prefer GHRS or HELP?

Do insiders & institutionals have more ownership in GHRS or HELP?

Which has more volatility and risk, GHRS or HELP?

Which has higher earnings and valuation, GHRS or HELP?

Does the media prefer GHRS or HELP?

Is GHRS or HELP more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HELP vs. The Competition

Cybin Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools